Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

Table 1

Basic study characteristics of included trials.

Author

Year

Country

Time Period

Patient Number

Age

Male/Female ratio

Grade

Hepatic resection (Y/N)

Hepatic Metastases

NOS score

Liver resection

Non-liver resection

G1/G2/G3

Unilobar/

Synchronous/

Bilobar

Metachronous

Birnbaum et al

2015

France

1995-2012

118

60 (31-82)

57 (20-83)

62/56

48/43/13

27/91

10/17

27/0

7

Xu et al

2015

China

2008-2013

36

49.9 ± 11.0

56.5 ± 12.5

14/22

6/26/4

26/10

25/11

NR

6

Partelli et al

2015

Italy

2000-2011

93

50 (45-59)

51.5 (43-63)

53/40

21/51/20

18/75

13/80

93/0

7

Zerbi et al

2013

Italy

2004-2007

45

56.9

60.6

26/19

13/19/11

9/36

NR

NR

6

Kleine et al

2011

German

1990-2009

15

55 (20-77)

NR

NR

9/6

NR

15/0

7

Mayo et al

2011

America

1985-2010

753

56 ± 12.6

57 ± 12.8

391/362

NR

339/414

223/530

273/480

8

House et al

2006

America

1988-2003

31

52 (31-71)

41 (31-52)

15/16

NR

26/5

NR

NR

9

Osborne et al

2006

America

2000-2004

120

56 ± 11.6

58 ± 11.1

64/56

NR

61/59

NR

NR

6

Musunuru et al

2006

America

1996-2004

48

56 (27-85)

NR

NR

13/35

14/34

28/20

7

Touzios et al

2005

America

1990-2004

42

58 ± 3

59 ± 3

17/25

NR

19/23

15/27

32/10

6

Solorzano et al

2001

America

1988-1999

100

NR

NR

56/44

NR

20/80

NR

NR

7

Chamberlain et al

2000

America

1992-1998

85

50 (20-79)

54 (23-79)

37/48

NR

34/51

14/71

63/22

7

Chen et al

1998

America

1984-1995

38

54 ± 4

59 ± 3

24/14

NR

15/23

17/21

NR

7

NR indicates no report.